Ono Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4528.T

Ono Pharmaceutical Co., Ltd. EPS (Diluted) for the year ending March 31, 2024: USD 1.76

Ono Pharmaceutical Co., Ltd. EPS (Diluted) is USD 1.76 for the year ending March 31, 2024, a 1.40% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Ono Pharmaceutical Co., Ltd. EPS (Diluted) for the year ending March 31, 2023 was USD 1.74, a 30.40% change year over year.
  • Ono Pharmaceutical Co., Ltd. EPS (Diluted) for the year ending March 31, 2022 was USD 1.33, a -2.36% change year over year.
  • Ono Pharmaceutical Co., Ltd. EPS (Diluted) for the year ending March 31, 2021 was USD 1.36, a 23.87% change year over year.
  • Ono Pharmaceutical Co., Ltd. EPS (Diluted) for the year ending March 31, 2020 was USD 1.10, a 21.83% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
Loading...
Tokyo Stock Exchange: 4528.T

Ono Pharmaceutical Co., Ltd.

CEO Mr. Gyo Sagara
IPO Date Jan. 4, 2001
Location Japan
Headquarters 8-2, Kyutaromachi 1-chome
Employees 4,258
Sector Health Care
Industries
Description

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Similar companies

4507.T

Shionogi & Co., Ltd.

USD 14.22

-0.40%

4578.T

Otsuka Holdings Co., Ltd.

USD 50.94

-0.33%

4523.T

Eisai Co., Ltd.

USD 27.10

0.38%

4503.T

Astellas Pharma Inc.

USD 9.60

0.25%

4519.T

Chugai Pharmaceutical Co., Ltd.

USD 43.03

0.75%

StockViz Staff

January 15, 2025

Any question? Send us an email